Subcutaneous Immunoglobulin (SCIg) Market by Application (Primary Immunodeficiency Diseases, Secondary Immunodeficiency Diseases, Neurological Disorders, Bleeding Disorders, Others) By End-user (Hospital, Homecare, Clinics) - Growth, Future Prospects & Competitive Analysis, 2015-2027

The Subcutaneous Immunoglobulin (SCIg) market is expected to cross-market at USD 8,435.62 million in 2027 from USD 2,136.71 million in 2020. It is expected to grow at a CAGR of over 20.73% during the forecast period.

The plasma collected from numerous donors and processed to remove contamination is called immune globulin. Immune globulin is free from contamination to maintain the safety and integrity of the products. Immune globulin can be delivered in multiple ways. Immune globulin administered subcutaneously is called Subcutaneous Immunoglobulin (SCIg). It contains antibodies that can fight against many bacteria and viruses.

Key Market Drivers and Restraints

The global Subcutaneous Immunoglobulin (SCIg) market report delivers a depth analysis of this industry with a detailed analysis of significant factors hindering the growth, mobilizing the demand and future growth prospects of the global Subcutaneous Immunoglobulin (SCIg) industry.

Impact of COVID 19

COVID-19 outbreak in early 2020 has resulted in severe supply chain disruption, resulting in a significant decline in demand and supply of Subcutaneous Immunoglobulin (SCIg) worldwide. However, the economies started taking pace in the later half of 2020, restoring the demand and supply. However, as the world enters the second quarter of 2021, the second and third wave of COVID-19 in most parts of Europe, India, Brazil, and the U.S. is likely to affect the demand and supply of Subcutaneous Immunoglobulin (SCIg). This, in turn, is expected to affect the growth rate of Subcutaneous Immunoglobulin (SCIg).

U.S. to Dominate the global Subcutaneous Immunoglobulin (SCIg) market

Key geographies analyzed in the global Subcutaneous Immunoglobulin (SCIg) market include Europe, North America, Asia Pacific, Latin America (LATAM), the Middle East, and Africa. The global Subcutaneous Immunoglobulin (SCIg) market is dominated by the U.S., with over 35% share in 2020. Strong demand from North America will likely drive the Subcutaneous Immunoglobulin (SCIg) market.

Global Subcutaneous Immunoglobulin (SCIg) Market is Led by Strong Demand from Primary Immunodeficiency Diseases

Global Subcutaneous Immunoglobulin (SCIg) market is categorized into Neurological Disorders, Secondary Immunodeficiency Diseases, Primary Immunodeficiency Diseases, Bleeding Disorders, etc. Primary Immunodeficiency Diseases accounted for over 60% of the total revenue generated by the global Subcutaneous Immunoglobulin (SCIg) industry in 2020. The primary Immunodeficiency Diseases application segment is also expected to exhibit the fastest CAGR among all applications of Subcutaneous Immunoglobulin (SCIg) during the forecast period.

The homecare segment will rule the global Subcutaneous Immunoglobulin (SCIg)industry over the forecast period.

Hospitals, Homecare, and Clinics are major end-user segments of the global Subcutaneous Immunoglobulin (SCIg) market. The homecare segment is poised to dominate the global Subcutaneous Immunoglobulin (SCIg) demand over the forecast period. It accounted for over 60% of the Subcutaneous Immunoglobulin (SCIg) market by end-users. The homecare segment is growing in popularity because of its convenience, cost-effectiveness, and the most sought-after way to administer Subcutaneous Immunoglobulin (SCIg).


Subcutaneous immunoglobulin is the biological molecules injected subcutaneously to cure certain diseases/disorders such as infectious diseases, immune deficiencies, and bleeding disorders, among others. Due to patient compliance, the preference for subcutaneous immunoglobulin is rising over the intravenous route of administration. The global subcutaneous immunoglobulin market is expected to witness lucrative growth during the forecast period owing to the growing burden of primary immunodeficiency diseases, the rising geriatric population, and opportunities for immunoglobulins for secondary immunodeficiency disease treatment.

The global subcutaneous immunoglobulin market is segmented based on the application, end-users, and geography. Based on the application, the global subcutaneous immunoglobulin market is segmented into secondary immunodeficiency diseases, primary immunodeficiency diseases, and other diseases. Other segments include neurological disorders, infectious diseases, bleeding disorders, etc. In 2017, the primary immunodeficiency diseases segment dominated the global market owing to the growing prevalence of such conditions and surging research and developments. Furthermore, the global market is segmented into home care, hospitals, and clinics based on the end-users. In 2017, the hospital segment led the market, and the homecare segment is the fastest-growing segment. The patient's preference and ease of use for the subcutaneous immunoglobulin administration accounted for the rapid growth of the homecare segments.

In 2017, North America accounted for a significant share of the global subcutaneous immunoglobulin market owing to the rise in the geriatric population, technological advancements, and the initial launch of products. According to the U.S. Census Bureau, the population equal to and above 60 years of age in the United States will rise to 12.67% in 2026 from 10.90%, which indicates the high demand for subcutaneous immunoglobulin during the forecast period. In addition, according to the Immune Deficiency Foundation, in 2015, approximately 55,000 patients in the United States were treated with primary immunodeficiency diseases, and the cases are expected to grow during the forecast period.

The manufacturers compete heavily in the market based on the pricing and the approaches to effectively deliver the immunoglobulin to the patient's body. For instance, Shire Plc has developed a product, Hyquia, which consists of a dual vial unit, one for immunoglobulin infusion of 10% and another for recombinant human hyaluronidase. The simultaneous subcutaneous administration of both the formulations enhances the bioavailability of the immunoglobulin and allows the infusion of large volumes.

This report offers:

  • The prominent end-users for subcutaneous immunoglobulin (SCIg) across geographies.
  • The regional market comparison for subcutaneous immunoglobulin and the most attractive region for expanding geographical outreach or product launch.
  • The current trends in the subcutaneous immunoglobulin market at the granular level
  • Market sizing of the global subcutaneous immunoglobulin market for ten years from 2016 to 2026 and quantifies the market's growth during the forecast period.
  • Mapping of the players based on the product offering, business strengths, strategic initiatives, product launches, geographical expansion, and profiling of major players.

Frequently Asked Questions

The market is impacted slightly from the COVID 19 pandemic and growth rate has been declined from over 18 to around 5%

Strong demand from Primary Immunodeficiency Diseases segment is expected to drive the demand for Subcutaneous Immunoglobulin (SCIg)

Biotest AG, CSL Limited, Grifols SA, Kedrion S.p.A, Octapharma AG, Takeda Pharmaceutical Company Limited (Shire), Bio Products Laboratory Ltd. and LFB S.A. are the key players operating in this market

Homecare segment is expected to exhibit fastest CAGR of over 20% during the forecast period

North America has the largest share owing to various developments happening in this space

Choose License Type
Trusted By
Published Date:  Apr 2021
Category:  Pharmaceuticals
Report ID:   59142
Report Format:   PDF
Pages:   190
Rating:    4.4 (60)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
24/7 Research Support